---
title: "Stifel Nicolaus Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285874282.md"
description: "Stifel Nicolaus analyst Paul Matteis has maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM) with a price target of $28.00, while the shares closed at $14.53. The analyst consensus is a Strong Buy with an average price target of $20.67, indicating a 42.26% upside. JonesTrading also reiterated a Buy rating with a $26.00 price target. Matteis is a 5-star analyst with a 15.9% average return and a 52.55% success rate in the Healthcare sector."
datetime: "2026-05-11T02:39:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285874282.md)
  - [en](https://longbridge.com/en/news/285874282.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285874282.md)
generator: "portal-rs"
---

# Stifel Nicolaus Remains a Buy on Contineum Therapeutics, Inc. Class A (CTNM)

Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Contineum Therapeutics, Inc. Class A on May 8 and set a price target of $28.00. The company’s shares closed last Friday at $14.53.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Matteis is a 5-star analyst with an average return of 15.9% and a 52.55% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Vertex Pharmaceuticals, and Xenon.

Currently, the analyst consensus on Contineum Therapeutics, Inc. Class A is a Strong Buy with an average price target of $20.67, implying a 42.26% upside from current levels. In a report released on May 8, JonesTrading also reiterated a Buy rating on the stock with a $26.00 price target.

### Related Stocks

- [CTNM.US](https://longbridge.com/en/quote/CTNM.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [IONS.US](https://longbridge.com/en/quote/IONS.US.md)
- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Contineum Therapeutics: Buy Rating Reiterated with PIPE-791 Upside Potential and Unchanged $26 Price Target](https://longbridge.com/en/news/297799155.md)
- [Contineum Therapeutics to present at Morgan Stanley Global Healthcare Conference](https://longbridge.com/en/news/297017645.md)
- [How Is Comcast’s Stock Performance Compared to Other Communication Stocks](https://longbridge.com/en/news/297602530.md)
- [Canaccord Genuity Sticks to Its Buy Rating for ACG Metals Limited Class A (ACG)](https://longbridge.com/en/news/297804740.md)
- [J.P. Morgan Sticks to Its Buy Rating for Eaglerock Land LLC Class A (EROK)](https://longbridge.com/en/news/297786686.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**